A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. - Mooradian, Meghan J.; Reuben, Alexandre; Prieto, Peter A.; Hazar-Rethinam, Mehlika; Frederick, Dennie T.; Nadres, Brandon; Piris, Adriano; Juneja, Vikram; Cooper, Zachary A.; Sharpe, Arlene H.; Corcoran, Ryan B.; Flaherty, Keith T.; et al. (OncoImmunology, 2018)